Skip to main navigation
Theratechnologies Inc. Theratechnologies Inc.

    About

  • About
    • About Us
    • Board of Directors
    • Leadership Team
    • Scientific Consultants & Advisors
    • Awards
  • Medicines & Pipeline

  • Medicines & Pipeline
    • Pipeline & Science
      • Hepatology
        • Tesamorelin for the Potential Treatment of NASH
        • Scientific Papers
        • Clinical Trials
        • Patient Information
      • Oncology
        • SORT1+ Technology™
        • TH1902
        • TH1904
        • Scientific Papers
        • Clinical Trials
        • Patient Information
      • HIV
        • F8 in HIV-Associated Excess Abdominal Fat
        • Scientific Papers
        • Clinical Trials
        • Patient Information
      • Expanded Access Policy
      • Grants/ISRs/IITs
  • IR Nav

  • Investors
    • Overview
    • News, Events & Presentations
      • Press Releases
      • Company Announcements
      • Events
      • Corporate Presentations
    • Stock Information
      • Quote & Chart
      • Historic Price Lookup
      • Investment Calculator
      • Analyst Coverage
    • Financial Information
      • SEC Filings
      • SEDAR Filings
      • Financial Reports
    • Corporate Governance
      • Documents & Charters
      • Board of Directors
      • Leadership Team
      • Committee Composition
    • Investor Resources
      • Contact IR
      • FAQs
  • Corporate Responsibility

  • Corporate Responsibility
  • Careers

  • Careers
  • Contact Us

  • Contact Us
  • en
    • en
    • fr
  • btn Alerts

  • Sign up for Email Alerts

Social icons

Press Releases

Investors

IR Nav

  • Overview
  • News, Events & Presentations
    • Press Releases
    • Company Announcements
    • Events
    • Corporate Presentations
  • Stock Information
    • Quote & Chart
    • Historic Price Lookup
    • Investment Calculator
    • Analyst Coverage
  • Financial Information
    • SEC Filings
    • SEDAR Filings
    • Financial Reports
  • Corporate Governance
    • Documents & Charters
    • Board of Directors
    • Leadership Team
    • Committee Composition
  • Investor Resources
    • Contact IR
    • FAQs

Stock

Prices shown in CAD

May 16, 2022 5:19 PM EDT

btn Stock

Learn More

IR Tools

  • Email Alerts
  • Contact IR
  • RSS Feeds

Press Releases

Latest

May 10, 2022
Appointments in Conjunction With Theratechnologies Annual Meeting
news
Press Releases
Apr 08, 2013
Theratechnologies Announces Termination of Agreement With Ferrer
Apr 03, 2013
Renegotiated Lease to Generate Substantial Annual Savings
Mar 25, 2013
Health Canada Decision Appealed
Mar 04, 2013
Health Canada Issues Decision on Tesamorelin
Feb 27, 2013
Theratechnologies Announces Financial Results for Fiscal Year 2012
Feb 14, 2013
Theratechnologies to Announce Financial Results for Fiscal Year 2012
Feb 05, 2013
Theratechnologies Announces Completion of NASDAQ Delisting
Jan 29, 2013
Theratechnologies Secures US Patent for its Novel Peptide TH1173
Jan 21, 2013
FDA approves alternative storage conditions for EGRIFTA™
Jan 14, 2013
Theratechnologies Announces Intent to Voluntarily Delist from NASDAQ
  • First page «
  • Previous page ‹
  • …
  • Page 20
  • Page 21
  • Page 22
  • Page 23
  • Page 24
  • Page 25
  • Page 26
  • Page 27
  • Current page 28
Displaying 271 - 280 of 280

Headquarters

Theratechnologies inc.
2015 Peel Street, 11th Floor
Montréal, Québec
Canada H3A 1T8
Phone: 514 336-7800
Fax: 514 331-9691

European Headquarters

Theratechnologies Europe Limited
2 Hume Street, 4th floor
Dublin 2
Ireland D02 DV24
Phone: +353 1 215 0650
europe@theratech.com

Investor Relations

Philippe Dubuc
Senior Vice President and Chief Financial Officer
Phone: +1 438-315-6608
ir@theratech.com

US Headquarters

Theratechnologies U.S., Inc.
101 Hudson Street
21st Floor
Jersey City, New Jersey 07302

Main Nav

  • Home
  • About
  • Medicines & Pipeline
  • Investors
  • Corporate Responsibility
  • Careers
  • Contact Us
©2022 - Theratechnologies Inc.

Legal Nav

  • Terms of Use
  • Privacy

Search

Theratechnologies